REYON Pharmaceutical Co., Ltd. (KRX:102460)
10,940
+150 (1.39%)
At close: Nov 4, 2025
REYON Pharmaceutical Revenue
REYON Pharmaceutical had revenue of 37.69B KRW in the quarter ending June 30, 2025, with 5.64% growth. This brings the company's revenue in the last twelve months to 150.05B, up 0.71% year-over-year. In the year 2024, REYON Pharmaceutical had annual revenue of 148.30B, down -1.83%.
Revenue (ttm)
150.05B
Revenue Growth
+0.71%
P/S Ratio
1.31
Revenue / Employee
341.03M
Employees
312
Market Cap
196.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 148.30B | -2.77B | -1.83% |
| Dec 31, 2023 | 151.07B | -2.97B | -1.93% |
| Dec 31, 2022 | 154.04B | 11.24B | 7.87% |
| Dec 31, 2021 | 142.80B | 12.77B | 9.82% |
| Dec 31, 2020 | 130.03B | -1.52B | -1.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |